by Laura Turbay | Dec 20, 2024
Cryptocurrency is having a moment. On the campaign trail, Trump vowed to make the US “the crypto capital of the planet.” After the election, Bitcoin stock catapulted to $90,000, a 40% rise compared to six months ago. This month its stock price...
by Laura Turbay | Nov 13, 2024
Eli Lilly lowered its revenue forecasts for the full year after an inventory drawdown by wholesalers weighed on sales for blockbuster weight loss and diabetes drugs. The stock fell 13% when markets opened on Wednesday. Both Mounjaro and Zepbound missed...
by Laura Turbay | Nov 13, 2024
The race to supply weight-loss drugs to nearly half of Americans that classify as obese, is on. Eli Lilly’s stock boomed after they released their blockbuster weight loss drug Zepbound last year, consecrating the Indiana-based drugmaker as one of the top...
by Laura Turbay | Oct 12, 2024
An experimental Eli Lilly drug for Alzheimer’s treatment was approved last week for use in Japan, which has one of the world’s largest aging populations. The U.S. Food and Drug Administration approved Kisunla to slow cognitive functional decline three months ago....
by Laura Turbay | Sep 23, 2024
Small-cap biotech stocks plundered after a 2021 wild-run, but investors are hopeful that interest rate cuts and positive test results in oncology and autoimmune treatments will be the right prescription for the biopharma market. That would be welcome news for...
